Biology subjects

Ongen, H.

Publications and source records attributed to Ongen, H..

3 recordsLinked to original sources

bioRxiv2018

Genomic dissection of Systemic Lupus Erythematosus: Distinct Susceptibility, Activity and Severity Signatures

Recent genetic and genomics approaches have yielded novel insights in the pathogenesis of Systemic Lupus Erythematosus (SLE) but the diagnosis, monitoring and treatment still remain largely empirical1,2. We reasoned that molecular characterization of SLE by whole blood transcriptomics may facilitate early diagnosis and personalized therapy. To this end, we analyzed genotypes and RNA-seq in 142 patients and 58 matched healthy individuals to define the global transcriptional signature of SLE. By controlling for the estimated proportions of circulating immune cell types, we show that the Interferon (IFN) and p53 pathways are robustly expressed. We also report cell-specific, disease-dependent regulation of gene expression and define a core/susceptibility and a flare/activity disease expression signature, with oxidative phosphorylation, ribosome regulation and cell cycle pathways being enriched in lupus flares. Using these data, we define a novel index of disease activity/severity by combining the validated Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)1 with a new variable derived from principal component analysis (PCA) of RNA-seq data. We also delineate unique signatures across disease endo-phenotypes whereby active nephritis exhibits the most extensive changes in transcriptome, including prominent drugable signatures such as granulocyte and plasmablast/plasma cell activation. The substantial differences in gene expression between SLE and healthy individuals enables the classification of disease versus healthy status with median sensitivity and specificity of 83% and 100%, respectively. We explored the genetic regulation of blood transcriptome in SLE and found 3142 cis-expression quantitative trait loci (eQTLs). By integration of SLE genome-wide association study (GWAS) signals and eQTLs from 44 tissues from the Genotype-Tissue Expression (GTEx) consortium, we demonstrate that the genetic causality of SLE arises from multiple tissues with the top causal tissue being the liver, followed by brain basal ganglia, adrenal gland and whole blood. Collectively, our study defines distinct susceptibility and activity/severity signatures in SLE that may facilitate diagnosis, monitoring, and personalized therapy.

genomics↗

bioRxiv2017

Hundreds of putative non-coding cis-regulatory drivers in chronic lymphocytic leukaemia and skin cancer

Perturbations of the coding genome and their role in cancer development have been studied extensively. However, the non-coding genomes contribution in cancer is poorly understood (1), not only because it is difficult to define the non-coding regulatory regions and the genes they regulate, but also because there is limited power owing to the regulatory regions small size. In this study, we try to resolve this issue by defining modules of coordinated non-coding regulatory regions of genes (Cis Regulatory Domains or CRDs). To do so, we use the correlation between histone modifications, assayed by ChIP-seq, in population samples of immortalized B-cells and skin fibroblasts. We screen for CRDs that accumulate an excess of somatic mutations in chronic lymphocytic leukaemia (CLL) and skin cancer, which affect these cell types, after accounting for somatic mutational patterns and biases. At 5% FDR, we find 90 CRDs with significant excess somatic of mutations in CLL, 60 of which regulate 126 genes, and in skin cancer 59 significant CRDs, 25 of which regulate 37 genes. The genes these CRDs regulate include ones already implicated in tumorigenesis, and are enriched in pathways already implicated in the respective cancers, like the B-cell receptor signalling pathway in CLL and the TGF{beta} signalling pathway in skin cancer. We discover that the somatic mutations in the significant CRDs of CLL are hitting bases more likely to be functional than the mutations in non-significant CRDs. Moreover, in both cancers, mutational signatures observed in the regulatory regions of significant CRDs deviate significantly from their null sequences. Both results indicate selection acting on CRDs during tumorigenesis. Finally, we find that the transcription factor biding sites that are disturbed by the somatic mutations in significant CRDs are enriched for factors known to be involved in cancer development. We are describing a new powerful approach to discover non-coding regions involved in tumorigenesis in CLL and skin cancer and this approach could be generalized to other cancers.

cancer biology↗

bioRxiv2017

Intra- and inter-chromosomal chromatin interactions mediate genetic effects on regulatory networks

Genome-wide studies on the genetic basis of gene expression and the structural properties of chromatin have considerably advanced our understanding of the function of the human genome. However, it remains unclear how structure relates to function and, in this work, we aim at bridging both by assembling a dataset that combines the activity of regulatory elements (e.g. enhancers and promoters), expression of genes and genetic variations of 317 individuals and across two cell types. We show that the regulatory activity is structured within 12,583 Cis Regulatory Domains (CRDs) that are cell type specific and highly reflective of the local (i.e. Topologically Associating Domains) and global (i.e. A/B nuclear compartments) nuclear organization of the chromatin. These CRDs essentially delimit the sets of active regulatory elements involved in the transcription of most genes, thereby capturing complex regulatory networks in which the effects of regulatory variants are propagated and combined to finally mediate expression Quantitative Trait Loci. Overall, our analysis reveals the complexity and specificity of cis and trans regulatory networks and their perturbation by genetic variation.

genomics↗